Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)

Sweden flag Sweden · Delayed Price · Currency is SEK
2.600
-0.020 (-0.76%)
Jul 25, 2025, 5:29 PM CET
-27.37%
Market Cap79.03M
Revenue (ttm)46.78M
Net Income (ttm)-11.33M
Shares Out30.40M
EPS (ttm)-0.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume72,681
Average Volume48,760
Open2.630
Previous Close2.620
Day's Range2.500 - 2.630
52-Week Range2.200 - 4.760
Beta1.31
RSI40.19
Earnings DateJul 9, 2025

About STO:NEWBRY

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. The company offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden. [Read more]

Sector Healthcare
Founded 2020
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol NEWBRY
Full Company Profile

Financial Performance

In 2024, STO:NEWBRY's revenue was 36.83 million, an increase of 258.75% compared to the previous year's 10.27 million. Losses were -15.41 million, -20.72% less than in 2023.

Financial Statements

News

There is no news available yet.